Coreg

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Coreg

What is Coreg? Identity and Dual-Action Classification

Property Description
Active ingredient Carvedilol
Form Oral tablets, Extended-Release Capsules
Pharmacological class Dual alpha- and beta-adrenergic receptor blocker
Common use Supports overall cardiovascular function
Origin Synthetic compound

Carvedilol is a synthetic, prescription-only medication classified as a cardiovascular agent and pharmacologically defined as a dual alpha- and beta-adrenergic receptor blocker. This classification identifies it as a compound engineered to interact with two different receptor types within the circulatory system simultaneously. Unlike earlier generations of compounds that solely targeted beta-receptors, Carvedilol’s dual-action profile provides a comprehensive approach to managing cardiovascular dynamics. This medication belongs to the beta-adrenergic blocking agents group and supports the regulation of processes related to heart function.

The single active ingredient in the medication is Carvedilol, a synthetic chemical entity belonging to the carbazole derivative family. This compound is delivered for oral administration, primarily available as standard oral tablets or as an extended-release capsule (known commercially by the specific brand extension Coreg CR). A key distinguishing factor of the extended-release formulation is its engineering for a sustained, 24-hour delivery profile, designed to provide stable drug concentration over time.

The overall purpose of the medication is to reduce strain and optimize the mechanical efficiency of the circulatory system through a dual-action mechanism. This combined physiological effect is achieved by both slowing the rate and force of the heart’s pumping action and, simultaneously, promoting the relaxation and widening of peripheral blood vessels (vasodilation). This integrated function helps to ensure the heart operates under less physical stress while efficiently circulating blood through a less restrictive vascular network, a process crucial for long-term support of cardiovascular health.

Regulatory References

  1. Carvedilol: MedlinePlus Drug Information
  2. FDA label for Coreg (Carvedilol)

What side effects are possible with Coreg?

Possible Side Effects and Safety Information

The safety profile for Coreg (Carvedilol) is officially classified by government regulatory authorities based on the frequency and system-organ class affected. This section describes the documented adverse reactions and safety constraints.


Adverse Reaction Frequencies and System Classes

The most frequently documented events, classified as very common (ge10%) in official labeling, include dizziness and fatigue (asthenia). Events classified as common (ge1% to le10%) frequently relate to the cardiovascular and metabolic systems, such as bradycardia (slow heart rate), hypotension (low blood pressure), weight increase, and hyperglycemia (high blood sugar). Less common events, noted in the regulatory documents, include syncope and atrioventricular block. Adverse reactions are grouped by System-Organ Class, encompassing Cardiac, Vascular, Nervous System, Gastrointestinal, and Metabolic disorders.


Serious Risks and Safety Constraints

Official labeling documents a critical safety constraint: the medication must not be abruptly discontinued. Doing so, especially in individuals with coronary artery disease, is associated with the risk of severe exacerbation of angina and myocardial infarction. Serious adverse reactions, such as Stevens-Johnson syndrome (SJS) and Toxic epidermal necrolysis (TEN), are documented in postmarketing reports as rare events.

Specific population-based safety constraints are also defined. Coreg is contraindicated (must not be used) in patients with severe hepatic impairment (severe liver problems) or bronchial asthma or related bronchospastic conditions. Furthermore, the label notes that the medication may mask symptoms of acute hypoglycemia in patients with diabetes mellitus and may worsen hyperglycemia.

Overdose and Emergency Response

Coreg overdose may result in severe manifestations affecting the cardiovascular, central nervous, and respiratory systems, as documented in official regulatory prescribing information. The expected clinical presentation includes severe hypotension (low blood pressure) and bradycardia (slow heartbeat). More serious, life-threatening outcomes can rapidly develop, such as cardiac arrest and cardiogenic shock. Additional documented signs include vomiting, bronchospasm, loss of consciousness, and generalized seizures.

Government regulatory sources require that individuals seek immediate medical attention or call emergency services if an overdose is suspected. Urgent medical help must be sought if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Management procedures described in official labels emphasize supportive measures and continuous observation. Treatment may include the specific administration of Atropine to address excessive bradycardia and Glucagon to help support cardiovascular function. Due to the systemic toxicity, patients may require monitoring and care under intensive-care conditions. The prescribing information also notes that the drug is not eliminable by dialysis due to high protein binding.

Therapeutic Uses of Coreg

What Coreg Treats: Main Uses and Benefits

Coreg is commonly used across conditions presenting with systemic or localized discomfort, assisting with symptom management where appropriate. This medication is applied across three relevant therapeutic domains: addressing symptoms associated with chronic heart failure; managing high blood pressure (hypertension); and providing supportive relief for stable angina (chest discomfort). It is utilized for managing heart failure and for easing symptoms that create noticeable physiological strain.

Easing Symptoms of Chronic Heart Failure

This medication is commonly used to help with Heart Overload Symptoms, such as intense fatigue, shortness of breath, and swelling (fluid retention) that create noticeable physiological strain. It contributes to improved day-to-day comfort and assists with maintaining functional stability.

Addressing High Blood Pressure Symptoms

Coreg is applied in addressing High Pressure Symptoms by managing consistently high blood pressure. This therapeutic benefit is relevant for easing symptoms related to systemic imbalance and supports general well-being during symptomatic phases.

Quick Fact: Relief for symptoms related to heightened physiological activity

Supportive Relief for Stable Angina

This medicine is relevant in contexts involving heightened systemic burden and used in situations involving certain distressing symptoms. It helps address groups of symptoms that may appear suddenly or fluctuate, offering symptomatic relief that helps patients cope more steadily with difficult episodes.

Regulatory References

  1. Carvedilol: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Coreg?

The population eligibility for Coreg (Carvedilol) is strictly defined by regulatory documents, distinguishing between populations who are permitted use, those for whom use is restricted, and those for whom use is strictly prohibited (contraindicated).

Contraindications (Must Not Use)

Coreg is contraindicated in patients with specific pre-existing conditions. These absolute prohibitions include individuals with severe hepatic impairment (severe liver disease), bronchial asthma or related bronchospastic conditions, severe bradycardia (very slow heart rate), cardiogenic shock, or those with second- or third-degree atrioventricular (AV) block unless a permanent pacemaker is in place.

Restricted and Not Established Use

Use is not recommended in the pediatric population (under 18 years of age) for all approved indications, as safety and effectiveness have not been established. Use during pregnancy is generally restricted and considered only if the potential benefit outweighs the potential risk. The medicine is also not recommended for women who are breastfeeding. Certain conditions, such as diabetes mellitus and peripheral vascular disease, require caution and close monitoring during use.

What should I know about interactions with other medicines?

Coreg Interactions with Other Medicines and Products

Official regulatory documents classify Coreg's interactions based on effects on drug exposure and physiological impact.

Interaction Type Interacting Agents / Classes Official Regulatory Statement
Metabolic (Pharmacokinetic) CYP2D6 Inhibitors (e.g., Fluoxetine, Paroxetine), CYP2C9 Inhibitors (e.g., Amiodarone), Rifampin, Cimetidine Inhibitors (e.g., CYP2D6 inhibitors) are expected to mathbfincrease the plasma concentration of the R(+) enantiomer. Rifampin mathbfdecreases overall carvedilol systemic exposure significantly. Cimetidine mathbfincreases carvedilol AUC by mathbf30%.
Transporter-Mediated (P-gp) Digoxin, Cyclosporine Carvedilol mathbfincreases the plasma concentrations of Digoxin (by mathbf14% to mathbf16%) and Cyclosporine through P-glycoprotein inhibition. Amiodarone further mathbfincreases the S(-) enantiomer concentration by mathbfge 2 -fold.
Physiological (Pharmacodynamic) Hypotensive Agents (e.g., Reserpine, MAO Inhibitors), Digitalis Glycosides, Calcium Channel Blockers (Verapamil, Diltiazem-type) Concomitant use with these agents may cause additive effects resulting in hypotension or mathbfsevere bradycardia due to enhanced reduction of heart rate or blood pressure.

Official Constraints and Population Notes

  • Timing Constraint: When discontinuing combined treatment with Clonidine, the mathbfbeta -blocking agent (carvedilol) must be discontinued first; Clonidine is then tapered several days later.
  • Administration Requirement: Carvedilol mathbfmust be taken with food to slow the rate of absorption and reduce the incidence of orthostatic effects.
  • Population Note: CYP2D6 Poor Metabolizers exhibit 2- to 3-fold mathbfhigher plasma concentrations of the R(+) enantiomer, which is noted to correlate with a higher rate of dizziness.

These mandated statements reflect the strict controls applied to co-administration to manage officially documented changes in drug exposure and physiological impact.

Mechanism of Action

How Coreg Works

Carvedilol's action is based on its dual capacity to act as an antagonist—blocking both alpha1 and beta-adrenergic receptors simultaneously. This dual antagonism modulates the Sympathetic Nervous System (SNS) signaling, which influences heart activity and blood vessel tone.


Modulation of Cardiac Activity (beta-Blockade)

This domain focuses on the beta1-adrenergic receptors predominantly located in the heart muscle. By blocking the binding of catecholamines to these sites, Carvedilol suppresses the signaling cascade that typically accelerates cardiac function. This mechanism leads directly to a negative chronotropic effect (slowing the intrinsic heart rate) and a negative inotropic effect (reducing the force of contraction), resulting in a reduction in the metabolic demands placed on the myocardium.


Regulation of Peripheral Vascular Tone (alpha1-Blockade)

This domain targets the alpha1-adrenergic receptors found in the smooth muscle of peripheral blood vessels. Blocking these receptors inhibits the signal that normally triggers muscle contraction and vasoconstriction (narrowing). The resulting relaxation and widening of the arteries, known as vasodilation, decreases the overall resistance to blood flow, thereby reducing the peripheral vascular resistance (afterload) which the ventricle must oppose for blood ejection.


The integrated effect of these two mechanisms results in simultaneous modulation of cardiac output and peripheral resistance of the vascular network.

Dosage and Administration Information

How Coreg is Used

The administration of carvedilol (Coreg) is restricted to the oral route using immediate-release tablets or extended-release capsules (Coreg CR). Both forms are typically taken with food to help regulate the rate of absorption and minimize potential orthostatic effects.

Administration and Frequency Patterns

The choice of formulation determines the frequency of use. The immediate-release tablets are typically administered twice daily, while the extended-release capsules are administered once daily, usually in the morning. A key requirement for the extended-release capsule is that it must be swallowed whole and should not be crushed, chewed, or divided.

General Dosing Principles and Titration

Carvedilol use is defined by a process of gradual dose adjustment, or up-titration, beginning with a low starting dose. The standard adult dosing regimens for immediate-release tablets begin at 3.125 mg twice daily for chronic heart failure or 6.25 mg twice daily for hypertension. The interval for dose adjustment varies based on the condition being managed:

  • Chronic Heart Failure (CHF): Dose adjustments occur at intervals of at least two weeks.
  • Hypertension and Post-Myocardial Infarction: Dose increases typically occur over successive intervals of seven to fourteen days.

Standard Adult Dosage Ranges

The maximum total daily dose for the treatment of hypertension with immediate-release tablets is 50 mg. For chronic heart failure, the maximum dose is generally 25 mg twice daily, though patients with a body weight greater than 85 kg may receive up to 50 mg twice daily. If treatment is discontinued for more than two weeks, the standard approach is to re-start at the lowest dose and repeat the full titration sequence.

Recent Clinical Evidence

Coreg: Recent Clinical Evidence

Clinical evidence for Coreg (carvedilol) primarily centers on its use in managing chronic heart failure (CHF) and hypertension (high blood pressure).


Findings in Chronic Heart Failure (CHF)

Major randomized controlled trials, such as the US Carvedilol Heart Failure Study and the COPERNICUS trial, have been foundational in establishing its use in heart failure patients who are also receiving standard therapy (like ACE inhibitors and diuretics).

  • Hospitalization and Mortality: Research in patients with mild-to-severe CHF demonstrated that adding carvedilol was associated with a reduction in the risk of death and the risk of hospitalization for cardiovascular causes. For instance, the COPERNICUS trial, focusing on patients with severe CHF, indicated a decrease in the risk of both mortality and hospitalization.
  • Left Ventricular Function: Studies have also shown that carvedilol therapy is associated with improvements in left ventricular ejection fraction (LVEF), a key measure of the heart's pumping ability, suggesting positive effects on cardiac remodeling.

Role in Hypertension and Post-MI

Carvedilol is also used to manage hypertension and left ventricular dysfunction following a myocardial infarction (heart attack) in clinically stable patients.

  • Post-MI: Trials focusing on patients who had recently survived a heart attack and had left ventricular dysfunction found that carvedilol was associated with a reduction in the risk of all-cause mortality and recurrent non-fatal myocardial infarction.
  • Metabolic Profile: Unlike some other beta-blockers, studies have suggested that carvedilol has a neutral or potentially beneficial effect on certain metabolic markers, such as lipid profiles and insulin sensitivity, which may be relevant for patients with co-existing conditions like diabetes.

Key Studies & References US Carvedilol Heart Failure Study Group: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure.

Frequently Asked Questions (FAQ)

Common questions about Coreg (FAQ)

Q: Is Coreg used only to treat high blood pressure?

A: According to the official product information, Coreg is not used solely for high blood pressure (hypertension). It is also prescribed to treat mild to severe chronic heart failure. Furthermore, it is used to manage left ventricular dysfunction following a heart attack in clinically stable patients.


Q: Does Coreg work immediately or does it take time to notice effects?

A: The maximum effect on lowering blood pressure generally occurs within one to two hours after taking a dose. However, Coreg treatment, especially for conditions like heart failure, is defined by a process of gradual dose adjustment over intervals of weeks or months. Because of this, the full therapeutic effect is assessed over time, rather than immediately.


Q: What does it mean that Coreg is a 'beta-blocker' in simple terms?

A: Coreg is a type of medicine that works by blocking certain natural substances, like adrenaline, in the body. This action results in a reduced heart rate and force of contraction. The dual action of Coreg also promotes vasodilation (the widening of blood vessels), resulting in a reduction of resistance to blood flow.


Q: What is the reason for monitoring blood pressure closely when initiating Coreg?

A: Blood pressure is monitored closely during the initial stages of treatment and when doses are increased. This is done to assess for orthostatic changes, which means watching for dizziness that can occur when standing up. This monitoring is performed to help identify any excessive reduction in blood pressure that may occur during the dose adjustment process.


Q: Are there any specific lifestyle changes mentioned in relation to taking Coreg?

A: General patient resources indicate that managing high blood pressure and heart health may involve lifestyle adjustments alongside medication. These adjustments may include optimizing diet, engaging in regular physical activity, and limiting alcohol and tobacco use. Official information emphasizes that Coreg must also be taken with food.


Q: What information is available regarding Coreg and its long-term safety?

A: Clinical studies have examined the long-term use of Coreg in severe heart failure patients. These studies have indicated an association with a reduction in the risk of death, hospitalizations, and recurrent heart attacks, supporting its established role in long-term cardiovascular care when administered to clinically stable individuals.


Q: How is Coreg described in official documents as different from other beta-blockers?

A: Coreg is classified as a dual alpha- and beta-adrenergic receptor blocker, which is its distinguishing feature. Its beta-blocking activity works primarily to slow the heart rate, while its alpha-blocking activity promotes vasodilation. This dual mechanism provides a combined physiological effect that differs from single-action beta-blockers.


Q: Are there known interactions between Coreg and over-the-counter pain medications like ibuprofen?

A: Official information indicates that Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which include common pain relievers like ibuprofen, may interact with Coreg. Combining these medications may reduce Coreg’s effectiveness in lowering blood pressure. This combination may also worsen fluid retention.


Q: Can consuming alcohol affect the way Coreg works?

A: Regulatory patient resources generally advise that using alcohol with certain medicines may cause interactions. Because Coreg is a hypotensive agent (it lowers blood pressure), combining it with alcohol may enhance this effect. This combination may potentially increase the risk of side effects like dizziness or fainting.


Q: Does Coreg affect a person's ability to drive or operate machinery?

A: Official warnings state that Coreg can cause side effects such as dizziness, tiredness, or fainting. For this reason, official warnings indicate that patients should avoid driving a car, using machinery, or performing tasks that require alertness until they know how the medicine affects them.


Q: Is Coreg considered appropriate for older adults?

A: Regulatory patient information specifically notes that older adults may experience increased sensitivity to the effects of Coreg. This sensitivity is primarily noted for side effects, especially dizziness and lightheadedness.


Q: How long does Coreg stay in the body after the last dose?

A: The apparent mean terminal elimination half-life of Coreg (carvedilol) is generally documented in regulatory data to range from 7 to 10 hours. This measurement describes the time it takes for the concentration of the drug in the body to be reduced by half.


Q: Does Coreg interact with common cold and flu remedies?

A: Some common cold and flu remedies contain ingredients known as sympathomimetic agents, such as phenylephrine. Official drug interaction information suggests that these agents may increase blood pressure when combined with a beta-blocker like Coreg, potentially counteracting the desired therapeutic effect.


Q: Are sleep disturbances or vivid dreams reported side effects of Coreg?

A: Regulatory adverse reaction reports list both sleepiness or unusual drowsiness and nightmares as less common side effects associated with Coreg use.


Q: Do regulatory documents mention any known interactions between Coreg and herbal supplements?

A: General safety information for beta-blockers indicates that close monitoring may be required when combining them with certain natural supplements. Some supplements, such as hawthorn, garlic, and ginkgo biloba, may enhance the blood pressure-lowering effects of the medication.


Q: Can Coreg cause hair loss?

A: Alopecia, the medical term for hair loss, is listed in the regulatory documentation for Coreg. It is noted as an uncommon side effect, meaning it is reported in less than 1% of patients.


Q: What effect does Coreg have on exercise or physical activity?

A: Regulatory patient information notes that exercise may be beneficial to the heart. This information suggests the patient review their physical activity and exercise plans with their healthcare provider to ensure it is appropriate for their specific condition while taking Coreg.


Q: Are there reports of Coreg causing problems with memory or concentration?

A: Regulatory adverse reaction reports include confusion and depression as less common side effects of Coreg. These effects are classified under nervous system and psychiatric disorders.


Q: What should be done if someone experiences cold hands or feet while taking Coreg?

A: Regulatory patient information notes that this drug may reduce blood flow to the hands and feet, which can cause them to feel cold. General patient guidance includes measures such as dressing warmly and avoiding tobacco use to help manage this effect.


Q: What are the official guidelines regarding missed doses when taking Coreg once daily?

A: Official guidelines describe the procedure for a missed dose: if a dose is missed, the patient should take it immediately upon remembering, unless it is close to the time for the next scheduled dose. If it is close to the next dose, the missed dose should be skipped entirely to return to the regular schedule; the patient should not take more than one dose at a time.

How should Coreg be stored and disposed of?

Storage Requirements

Coreg (carvedilol) tablets must be stored at Controlled Room Temperature, which is officially defined as 20^circ to 25 C (68^circ to 77 F), with permitted short excursions up to 30 C. To maintain product stability, the tablets must be protected from moisture and kept dry. Official regulatory requirements further state that the medicine should be dispensed and stored in a tight, light-resistant container.

Child Safety and Disposal

All medication, including Coreg, must be kept out of the reach of children. For disposal, regulatory guidance states that unused or expired medicine should not be disposed of via wastewater, and disposal through routine household waste should be avoided. The proper procedure is to safely throw away the tablets and dispose of the product according to local pharmaceutical regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Coreg found in:

A-Z Index: